Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden
Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden have?
Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden has 19 citations in the OpenAlex counts ScholarIQ stores.
When was Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden published?
Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden has 2016 year in the ScholarIQ index.
What is the open-access status of Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden?
Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden has bronze oa status in the ScholarIQ index.
What is the DOI of Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden?
The DOI for Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden is on the source record.
What is the PMID of Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden?
The PMID for Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden is on the source record.
What is the OpenAlex record for Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden?
The OpenAlex for Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden is on the source record.